Morningstar - Bank of Montreal (BMO.) Growth in the U.S. Continues for BMO in 2019

Report

Morningstar

Eric Compton

EUR 100.00 For Business Accounts Only

Growth in the U.S. Continues for BMO in 2019

Narrow-moat rated Bank of Montreal reported good fiscal first-quarter results. These results fit well within our long-term thesis on the company, and we do not plan any material changes to our fair value estimate of CAD 105 for Canadian shares (USD 79 for U.S. shares). The bank had strong EPS growth of 10% for the quarter, with earnings increasing to CAD 2.32 per share. BMO reported a 13.9% adjusted return on equity for the quarter, exactly in line with adjusted results from first-quarter 2018. ...

29/05/2019 13 EN

Underlying

Bank of Montreal

Bank of Montreal is a financial services organization. Co. provides a range of retail banking, wealth management and investment banking products and services. Co. serves its clients through three operating groups: Personal and Commercial Banking, which provides financial services to personal and commercial customers; Private Client Group, which provides wealth management products and services to individuals and select institutional segments; and BMO Capital Markets, which provides clients financial and capital markets services to corporate, institutional and government clients.

See profile

CA0636711016 Toronto Stock Exchange Canada

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Eric Compton

Other Reports on these Companies

SmartInsider

Bank Of Montreal: 2 directors

Two Directors at Bank Of Montreal sold/sold after exercising options 5,468 shares at between 148.042CAD and 148.865CAD. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity ...

Free Trial

March 5, 2025 March 5, 2025 1 EN

Moody's Investors Service

Bank of Montreal: Revenue growth across all segments drives solid Q1 results; capitalization robust

BMO's Q1 2025 earnings reflect broad-based revenue growth across all business segments, partly offset by higher expenses and a higher provision for credit losses.

EUR 171.30

February 27, 2025 February 27, 2025 1 EN

Moody's Investors Service

Bank of Montreal: Revenue growth across all segments drives solid Q1 results; capitalization robust

BMO's Q1 2025 earnings reflect broad-based revenue growth across all business segments, partly offset by higher expenses and a higher provision for credit losses.

EUR 171.30

February 26, 2025 February 26, 2025 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Growth in the U.S. Continues for BMO in 2019

Bank Of Montreal: 2 directors

Bank of Montreal: Revenue growth across all segments drives solid Q1 results; capitalization robust

Bank of Montreal: Revenue growth across all segments drives solid Q1 results; capitalization robust

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe